Biological testing and development of a wound healing product

Description

Chronic wounds, such as diabetic foot ulcers, represent a significant burden on healthcare systems, both medically and economically.

They occur when the balance between inflammatory processes and tissue repair is disrupted. Promising therapeutic approaches focus on the use of autologous blood to actively promote wound healing. The new FastSkin system (mimiX Biotherapeutics Ltd.) offers an innovative approach to autologous blood therapy.

Our Projects:

Physicochemical testing of the FastSkin wound healing product in preparation for its approval as a medical device.
Development of the next-generation product, including the investigation of how sound wave technology influences wound healing.